Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
 

(00:32)
 Could you provide us with a little bit of information about yourself and your background?

(01:18)
 Can you start with a brief overview of the assay?

(02:13)
 Which patients should have this testing and when should it be performed?

(03:21)
 Are there alternative test options available and how do those compare with the folate receptor alpha assay?

(03:57)
 How are the results used in patient care?